LLY

Lilly
NYSE

Real-time Quotes | Nasdaq Last Sale

149.81
-0.05
-0.03%
After Hours: 149.01 -0.8 -0.53% 19:53 09/23 EDT
OPEN
150.05
PREV CLOSE
149.86
HIGH
151.59
LOW
148.70
VOLUME
3.55M
TURNOVER
--
52 WEEK HIGH
170.75
52 WEEK LOW
101.36
MARKET CAP
143.29B
P/E (TTM)
24.37
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sanofi Reports Positive Lung Cancer Data, And Other News: The Good, Bad And Ugly Of Biopharma
Sanofi reports positive data for pivotal lung cancer trial.AstraZeneca announces positive data for Lynparza in prostate cancer.Amgen reports encouraging data for investigational Sotorasib.
Seekingalpha · 12h ago
Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps
Investor's Business Daily · 1d ago
Eli Lilly (LLY) Presents At ESMO Virtual Congress 2020 - Slideshow
The following slide deck was published by Eli Lilly and Company in conjunction with this event.
Seekingalpha · 1d ago
Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease
New indication reflects distinct patient population in the REWIND study – people with type 2 diabetes with multiple cardiovascular risks or established cardiovascular diseaseTORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the
GlobeNewswire · 1d ago
P/E Ratio Overview: Eli Lilly
In the current market session, Eli Lilly Inc. (NYSE: LLY) is trading at $150.32, after a 0.6% decrease. However, over the past month, the stock went up by 0.36%, and in the past year, by 34.86%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing
Benzinga · 1d ago
Raymond James Ltd. Names Jennifer Hodgson to Lead Canadian Trust Operations
TORONTO, Sept. 22, 2020 /CNW/ - Raymond James Ltd.
CNW Group · 1d ago
Eli Lilly Announces Trulicity Now Indicated As Adjunct To Diet, Exercise, Standard Of care Therapy To Reduce Risk Of Non-Fatal Stroke In Adults With Type 2 Diabetes Mellitus
Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular
Benzinga · 1d ago
Eli Lilly Could Rally After Passing the Test
Drug maker Eli Lilly (LLY) could rally after its 200-day average test....LLY
TheStreet.com · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LLY. Analyze the recent business situations of Lilly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LLY stock price target is 166.64 with a high estimate of 189.00 and a low estimate of 120.00.
EPS
Institutional Holdings
Institutions: 1.65K
Institutional Holdings: 778.68M
% Owned: 81.41%
Shares Outstanding: 956.47M
TypeInstitutionsShares
Increased
464
35.89M
New
86
3.85M
Decreased
650
55.42M
Sold Out
146
7.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.52%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Ricks
Chief Financial Officer/Senior Vice President
Joshua Smiley
Senior Vice President/Chief Information Officer
Aarti Shah
Senior Vice President/Chief Scientific Officer
Daniel Skovronsky
Senior Vice President/Chief Compliance Officer
Melissa Barnes
Senior Vice President/General Counsel
Anat Hakim
Senior Vice President/Director of Human Resources
Stephen Fry
Senior Vice President
Patrik Jonsson
Senior Vice President
Michael Mason
Senior Vice President
Johna Norton
Senior Vice President
Myles O'Neill
Senior Vice President
Leigh Pusey
Senior Vice President
Anne White
Senior Vice President
Alfonso Zulueta
Lead Director/Independent Director
Juan Luciano
Independent Director
Raul Alvarez
Independent Director
Ralph Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn Bertozzi
Independent Director
Michael Eskew
Independent Director
J. Erik Fyrwald
Independent Director
Jamere Jackson
Independent Director
William Kaelin
Independent Director
Marschall Runge
Independent Director
Kathi Seifert
Independent Director
Jackson Tai
Independent Director
Karen Walker
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/15/2020
Dividend USD 0.74
08/13/2020
05/04/2020
Dividend USD 0.74
05/14/2020
12/16/2019
Dividend USD 0.74
02/13/2020
10/21/2019
Dividend USD 0.645
11/14/2019
06/19/2019
Dividend USD 0.645
08/14/2019
05/06/2019
Dividend USD 0.645
05/16/2019
12/19/2018
Dividend USD 0.645
02/14/2019
10/15/2018
Dividend USD 0.563
11/14/2018
06/18/2018
Dividend USD 0.563
08/14/2018
05/07/2018
Dividend USD 0.563
05/16/2018
12/11/2017
Dividend USD 0.563
02/14/2018
10/16/2017
Dividend USD 0.52
11/14/2017
06/19/2017
Dividend USD 0.52
08/11/2017
05/01/2017
Dividend USD 0.52
05/11/2017
12/13/2016
Dividend USD 0.52
02/13/2017
10/18/2016
Dividend USD 0.51
11/10/2016
06/20/2016
Dividend USD 0.51
08/11/2016
05/02/2016
Dividend USD 0.51
05/11/2016
12/08/2015
Dividend USD 0.51
02/10/2016
10/19/2015
Dividend USD 0.5
11/10/2015
06/15/2015
Dividend USD 0.5
08/12/2015
05/04/2015
Dividend USD 0.5
05/14/2015
12/15/2014
Dividend USD 0.5
02/11/2015
10/20/2014
Dividend USD 0.49
11/12/2014
06/16/2014
Dividend USD 0.49
08/13/2014
05/05/2014
Dividend USD 0.49
05/13/2014
12/16/2013
Dividend USD 0.49
02/12/2014
10/21/2013
Dividend USD 0.49
11/13/2013
06/18/2013
Dividend USD 0.49
08/13/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LLY
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eli Lilly And Co stock information, including NYSE:LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.